Home › Asthma › South Carolina
Pag-aaral pangklinika para sa Asthma sa South Carolina
7 pag-aaral para sa Asthma ang naghahanap ng mga kalahok sa mga site sa South Carolina.
Opisyal na teksto ng pag-aaral (English)
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
- Research Site, Charleston
Nagre-recruitPhase 3
Edad 12 hanggang 17 · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT06307665A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
- Clinical Research of Rock Hill, Rock Hill
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT06977581A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)
- GSK Investigational Site, Spartanburg
- GSK Investigational Site, Spartanburg
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07645248A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
- Research Site 16, Rock Hill
Nagre-recruitPhase 3
Edad 12 hanggang 80 · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07359846Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
- Research Site, Rock Hill
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT06932263ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
- Enveda Investigative Site, North Charleston
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 24, 2026 · NCT07301255A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma
- Research site, Rock Hill
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hul 28, 2026 · NCT07532265Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.